Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed patches of skin, often linked to immune system dysfunction and environmental factors.
Ranked by community outcomes, then evidence grade, Health Voice mentions, and recency.
Why it may help Eczema (Atopic Dermatitis): Zinc may help alleviate eczema by supporting immune function and skin barrier integrity, which can reduce inflammation and promote healing of damaged skin.
Why it may help Eczema (Atopic Dermatitis): Vitamin D may help alleviate eczema symptoms by modulating immune responses and enhancing skin barrier function, which reduces inflammation and improves skin integrity.
Why it may help Eczema (Atopic Dermatitis): Aloe Vera may soothe eczema by providing anti-inflammatory and moisturizing compounds that reduce skin irritation, promote healing, and improve skin barrier function.
Why it may help Eczema (Atopic Dermatitis): Calendula may help soothe eczema by reducing inflammation and promoting skin healing through its anti-inflammatory and antiseptic properties, which can alleviate irritation and support skin repair.
Licorice root is an herb with a sweet taste, traditionally used for various ailments, but its potential health benefits and safety require further scientific investigation.
Why it may help Eczema (Atopic Dermatitis): Omega-3 fish oil may help reduce eczema symptoms by decreasing systemic inflammation and modulating immune responses, which can alleviate skin redness and itching.
Why it may help Eczema (Atopic Dermatitis): Evening Primrose Oil may improve eczema by providing gamma-linolenic acid (GLA), which the body converts into anti-inflammatory compounds, reducing skin inflammation and dryness.
Aerobic and resistance exercise have RCT-grade evidence for depression, comparable to SSRIs in mild-moderate cases.
Why it may help Eczema (Atopic Dermatitis): Probiotics may help alleviate eczema by modulating the gut microbiome and immune system, which can reduce systemic inflammation and improve skin barrier function.
Why it may help Eczema (Atopic Dermatitis): Chamomile may soothe eczema by reducing inflammation and promoting skin healing through its anti-inflammatory and antioxidant compounds, which can alleviate itching and irritation.
Community outcomes
Self-reported by community members · not medical advice.
Self-reported community outcomes. Not medical advice. Requires at least three reports per remedy to surface.
Community outcome data is still being collected for this ailment.
Be the first to share your experience →As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.
Structured experience reports from people managing this condition. Not medical advice.
You can share without an account — we'll send a one-time code to verify your email. Or sign in.
Loading posts…
Community Discussions
How global health authorities view Eczema (Atopic Dermatitis).
The National Eczema Association (NEA) and American Academy of Dermatology (AAD) emphasize the importance of moisturizers, trigger avoidance, and conventional medications. While they acknowledge the public's interest in natural remedies, they generally advise caution due to limited robust scientific evidence for many alternative treatments. The National Center for Complementary and Integrative Health (NCCIH) states that some dietary supplements, like probiotics and omega-3 fatty acids, have been studied for eczema, but results are mixed and more research is needed. They highlight that topical emollients and wet wrap therapy are well-established supportive measures. The Cochrane Library has reviewed some interventions, finding some promise for probiotics in preventing eczema in high-risk inf
Indexed studies for Eczema (Atopic Dermatitis), grouped by source type and quality.
Filter by source type
Pooled analyses across multiple human trials.
Yu M, Zhang Q, Chen J, Yang J, Bai Z, Wang J · Frontiers in pediatrics · 2025
This meta-analysis investigates the association between maternal anxiety/depression during pregnancy and the development of eczema/atopic dermatitis (AD) in offspring. A literature search was conducted across four electronic databases (PubMed, Web of Science, Embase, and the Cochrane Library) for studies published from database inception until July 2025. In this study, maternal depression and anxiety were defined as conditions physician-diagnosed or assessed with standardized scales during pregnancy. The primary outcome was the incidence of eczema/AD in the offspring. A total of 12 cohort studies were included in this meta-analysis. Pooled results indicated that maternal depression [odds ratio (OR) = 1.06, 95% confidence interval (95% CI) = 1.01-1.11, p = 0.015] or anxiety (OR = 1.11, 95% CI = 1.03-1.19, p = 0.005) during pregnancy was potentially associated with a higher incidence of offspring eczema
Structured reviews of the full body of evidence (incl. Cochrane).
Demidova A, Kiknavelidze N, Purtskhvanidze K, Alieva E, Ebrahimnejad M, Konchina S · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
Heterogeneity in outcome reporting and inconsistent use of outcome measurement instruments in allergy and clinical immunology research affects the comparability, synthesis, and clinical applicability of study findings. Harmonisation efforts, particularly Core Outcome Set (COS) development, aim to address these challenges by establishing standardised, evidence-based and consensus-driven outcome recommendations. This systematic review aims to map available COS and other harmonisation processes (HP) in allergy and clinical immunology, evaluate their methodological approaches, and assess their alignment with established development standards. We systematically searched MEDLINE, EMBASE, and the COMET Initiative database until June 7, 2024 to identify COS and HP. We included studies if they provided recommendations on 'core' outcomes and/or outcome measurement instruments. Data extraction included disease focus, methodological approach, stakeholder involvement, and adherence to the Core Out
Controlled human studies with random assignment.
Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A · Clinical and experimental dermatology · 2022 · n=10
Eczema (atopic dermatitis; AD) is a very common itchy skin condition affecting 1 in 5 children and up to 1 in 10 adults worldwide. The skin of eczema sufferers is prone to redness, irritation and dryness because it does not form an effective barrier, i.e. the ability of the skin to stop irritants, allergens and microorganisms getting into the body. Skin barrier dysfunction is a hallmark of AD. The regular and liberal (600 g/week for an adult) use of emollients is recommended for all patients with eczema), even between episodes of itching and redness, to soften and soothe the skin. In England alone, almost 9 million prescriptions for emollient creams were issued in 2018, at a cost of over £50 million. Despite this widespread use, relatively little is known about how commonly prescribed emollient creams affect the skin's barrier, and thus the role of moisturizers in AD development and progression remains unclear. We set out to compare three different types of em
Clinical Evaluation of a Nature-Based Bakuchiol Anti-Aging Moisturizer for Sensitive Skin.
Draelos ZD, Gunt H, Zeichner J, Levy S · Journal of drugs in dermatology : JDD · 2020
Patients with sensitive skin find topical retinoid use for anti-aging purposes challenging due to irritation. Bakuchiol, a meroterpene from the Psoralea corylifolia seed, has retinol functionality through retinol-like regulation of gene expression. This research examined the tolerability, efficacy, and barrier effects of a nature-based bakuchiol-containing cleanser and moisturizer in subjects with sensitive skin. 60 female subjects Fitzpatrick skin types I–V age 40–65 years with sensitive mild to moderate photodamaged skin were enrolled in this 4 week study. A sensitive skin panel was constructed: 1/3 eczema/atopic dermatitis, 1/3 rosacea, 1/3 cosmetic intolerance syndrome. Subjects used a nature-based cleanser and moisturizer twice daily and underwent transepidermal water loss (TEWL), corneometry, tolerability assessments, and efficacy assessments at baseline, 5–10 minutes post-application, and week 4. The skin care products were well tolerated and eff
Draelos ZD, Levy SB, Lutrario C, Gunt H · Journal of drugs in dermatology : JDD · 2018 · n=120
Unique whole formula nature-based sensitive skin products are formulated to minimize irritation while providing conditioning and soothing benefits to clinically diagnosed sensitive skin. To evaluate and compare the efficacy and tolerability of a regimen of cleanser containing natural oils, beeswax, and witch hazel, and day & night creams containing natural oils, glycerin, and botanical anti-inflammatories (NR); and a synthetic dermatologist-recommended regimen of cetyl alcohol, sodium lauryl sulphate-containing cleanser and glycerin, polyisobutene-containing lotion (CR) in clinically diagnosed sensitive skin resulting from eczema/atopic dermatitis, rosacea, or cosmetic intolerance. 120 subjects were randomized to receive either NR or CR, twice daily for 4 weeks in this double-blind study. Blinded investigator-rated and subject-rated overall skin appearance was assessed using a 5-point scale (0=none, 4=severe) at baseline, 2 weeks, and 4 weeks. Noninvasive skin assessments for ski
Cohort, case-control, and cross-sectional human studies.
Wang Z, Zhang L, Fan R, Shi J, Qin M, Xu S · Dermatology and therapy · 2025
Treat-to-target (T2T) strategies have been adopted in atopic dermatitis (AD) management, which defines specific moderate/acceptable and optimal targets for reducing disease severity. However, real-world evidence on the achievement rates of these targets remains limited. This prospective observational study enrolled patients with moderate-to-severe AD without treatment protocol modifications. Disease severity was longitudinally assessed using 5-point Patient Global Impression of Severity (PGIS-5), Peak Pruritus Numerical Rating Scale (pp-NRS), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Body Surface Area (BSA), Eczema Area and Severity Index (EASI), and Scoring Atopic Dermatitis (SCORAD) at baseline and weeks 2, 4, 8, and 16. Treatment responses were compared against two established T2T frameworks: the T2T consensus (de Bruin-Weller et al.) and Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations (Silverberg et al.). Target feasib
Zhang K, Zeng M, Lei L, Fu C, Huang J, Zhou S · Postgraduate medical journal · 2025
Observational studies have suggested a potential link between emotions and inflammatory dermatoses. However, research on the causal relationship between different types of emotions and inflammatory dermatoses is lacking. This study is aimed to investigate the causal relationship between negative emotions and inflammatory dermatoses through Mendelian randomization (MR) analysis. Summary data of seven negative emotions were obtained from a genome-wide association study (GWAS) conducted by the MRC-IEU consortium. Seven inflammatory dermatoses including vitiligo, psoriasis, systemic lupus erythematosus, eczema, atopic dermatitis, acne, and rosacea were obtained from published GWAS. The MR analysis primarily employed the Inverse variance weighted (IVW) method, and supplemented by MR-Egger and other three MR methods. The IVW method revealed that guilty feelings have potential to increase the risk of psoriasis (OR = 1.02, 95% CI: 1.00-1.05, P = 0.019), while worr
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y · Dermatology and therapy · 2025 · n=1124
The Aiming High in Eczema/Atopic Dermatitis (AHEAD) guidelines recommend achieving minimal disease activity (MDA) in atopic dermatitis (AD), defined as simultaneous achievement of optimal treatment targets for at least one clinician- and one patient-reported outcome (ClinRO + PRO). We assessed the effect of upadacitinib on achieving optimal ClinROs, optimal PROs, and MDA in Measure Up 1 (NCT03569293) and Measure Up 2 (NCT3607422) studies for patients with moderate to severe AD. Patients were randomized to receive upadacitinib (15 mg or 30 mg) or placebo. Achievement of ≥ 1 optimal target in ClinROs, ≥ 1 optimal target in PROs, and MDA (≥ 1 optimal ClinROs and ≥ 1 optimal PROs) were reported at weeks 16 (upadacitinib vs placebo) and 52 (upadacitinib only). MDAs in selected combinations were also assessed at weeks 16 and 52. A total of 1683 and 1124 patients were included in the week 16
Preclinical animal research — not a substitute for human evidence.
Fu Z, Xie Y, Zeng L, Gao L, Yu X, Tan L · Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
Ozone is widely applied to treat allergic skin diseases such as eczema, atopic dermatitis, and contact dermatitis. However, the specific mechanism remains unclear. This study aims to investigate the effects of ozonated oil on treating 2,4-dinitrochlorobenzene (DNCB)-induced allergic contact dermatitis (ACD) and the underling mechanisms. Besides the blank control (Ctrl) group, all other mice were treated with DNCB to establish an ACD-like mouse model and were randomized into following groups: a model group, a basal oil group, an ozonated oil group, a FcεRI-overexpressed plasmid (FcεRI-OE) group, and a FcεRI empty plasmid (FcεRI-NC) group. The basal oil group and the ozonated oil group were treated with basal oil and ozonated oil, respectively. The FcεRI-OE group and the FcεRI-NC group were intradermally injected 25 µg FcεRI overexpression plasmid and 25 µg FcεRI empty plasmid when treating with ozonated oil, respectively. We rec
Curated cross-source summaries (TRIP Database and similar).
Cochrane Reviews on Atopic Eczema
Cochrane
Cochrane provides systematic reviews and meta-analyses of healthcare interventions, offering high-quality evidence summary for various treatments and management strategies for atopic eczema. This is a search result page for relevant reviews.
TRIP Database search for Atopic Dermatitis
TRIP Database
The TRIP Database is a clinical search engine designed to allow health professionals to quickly and easily find high-quality research evidence to support their practice, including on topics surrounding Atopic Dermatitis.
TRIP Database | Atopic Dermatitis
TRIP Database
TRIP is a clinical search engine designed to allow users to quickly and easily find high-quality research evidence to support their practice for conditions like atopic dermatitis.
Conventional medical treatment for eczema typically involves topical corticosteroids to reduce inflammation and itching, calcineurin inhibitors, and antihistamines for itch relief. In severe cases, systemic medications like oral corticosteroids, immunosuppressants, or newer biologic drugs may be prescribed. Phototherapy is also an option for some individuals. A dermatologist can help develop a per
Latest News
Health Videos
This information is for educational purposes only and not a substitute for professional medical advice. Always consult with a qualified healthcare provider before making any decisions about your health or treatment, especially if you have eczema or other chronic conditions.
Found something that helped your eczema (atopic dermatitis)?
Help others see what actually works.
Found something that helped your eczema (atopic dermatitis)?
Real-world results help others choose what's worth trying.